Inflammatory Bowel Disease Questionnaire
Also known as: IBDQ, IBD Questionnaire, Inflammatory Bowel Disease QoL
The IBDQ is a disease-specific quality of life measure for inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. Developed by Elena Irvine and colleagues in 1994, this 32-item questionnaire measures how IBD affects bowel function, systemic symptoms, emotional well-being, and social functioning. It is the most widely used quality-of-life instrument in IBD research and clinical practice.
Key highlights
- IBD-specific and comprehensive—developed from IBD patient interviews, capturing disease-relevant domains (bowel symptoms, urgency, fatigue, emotional impact, social limitation) that generic QoL measures miss
- Multidimensional—four subscales enable targeted intervention planning (e.g., dietary, pharmacologic for bowel symptoms; psychological for emotional burden)
- Extensively validated—used in hundreds of IBD trials and cohort studies with demonstrated reliability (Cronbach's α 0.80-0.95) and responsiveness to biologic and conventional therapies
- Free and universally accessible—no licensing restrictions; downloadable forms and scoring algorithms from academic centers
- Short-form available—Short IBDQ (10 items, 3-5 minutes) provides rapid assessment in routine clinic when full IBDQ is impractical
Intuition
This section is available to Pro members. Upgrade to Pro
How it works
This section is available to Pro members. Upgrade to Pro
When to use it
The IBDQ is indicated for comprehensive quality-of-life assessment in IBD populations. Use cases include baseline assessment at diagnosis to establish disease burden and guide patient education, monitoring during biologic therapy (TNF inhibitors, interleukins) to assess patient-experienced benefit, outcome measurement in IBD trials as a primary or co-primary endpoint, research examining long-term natural history and psychosocial consequences, and quality improvement in gastroenterology practice. The IBDQ is particularly valuable for patients in remission or with persistent symptoms despite biochemical remission, where patient-centered assessment reveals residual burden. It is less suitable for acute flare assessment (use symptom scales) or non-IBD populations.
Strengths & limitations
- IBD-specific and comprehensive—developed from IBD patient interviews, capturing disease-relevant domains (bowel symptoms, urgency, fatigue, emotional impact, social limitation) that generic QoL measures miss
- Multidimensional—four subscales enable targeted intervention planning (e.g., dietary, pharmacologic for bowel symptoms; psychological for emotional burden)
- Extensively validated—used in hundreds of IBD trials and cohort studies with demonstrated reliability (Cronbach's α 0.80-0.95) and responsiveness to biologic and conventional therapies
- Free and universally accessible—no licensing restrictions; downloadable forms and scoring algorithms from academic centers
- Short-form available—Short IBDQ (10 items, 3-5 minutes) provides rapid assessment in routine clinic when full IBDQ is impractical
- Does not assess disease activity objectively—IBDQ measures quality of life, not inflammation (CRP, calprotectin, endoscopy); both must be assessed independently
- Modest correlation with biomarkers—IBDQ score correlates moderately with inflammatory markers (r = 0.30-0.50) and endoscopic severity; patients in remission biochemically may report low IBDQ if persistent symptoms remain
- Length for full form—32 items require 10-15 minutes; patients with severe diarrhea or fatigue may find completion burdensome
- Multiple response scales—varying Likert anchors across items may confuse some respondents; digital administration with clear instructions helps
- Limited pediatric validation—IBDQ was developed for adults; use pediatric IBD-specific measures for children
Common pitfalls
This section is available to Pro members. Upgrade to Pro
Applications
This section is available to Pro members. Upgrade to Pro
Frequently asked
A patient is in biochemical remission (normal CRP) but has IBDQ 130 (low). What explains this?
Biochemical remission reflects anti-inflammatory success but does not guarantee symptom control or quality of life. This patient may have persistent bowel urgency, loose stools, or fatigue despite normal biomarkers. Assess: (1) medication adherence and timing; (2) dietary triggers (fiber, lactose, fat) and food intolerance; (3) anxiety/depression (low Emotional subscale score); (4) irritable bowel syndrome overlap (persisting post-inflammation). Targeted intervention: dietary consultation, antidiarrheals, psychological support, or consideration of supplemental biologic.
Should I use full IBDQ or Short IBDQ for routine monitoring?
Use Short IBDQ for routine clinic visits (faster, 3-5 minutes, still captures overall QoL). Use full IBDQ (32 items) at baseline and in research contexts where dimensional detail guides intervention. Short IBDQ correlates highly with full IBDQ (r > 0.95) for overall assessment.
How much IBDQ improvement indicates clinically meaningful change?
A change of 16-20 points on full IBDQ (or proportionally on Short IBDQ) represents minimum clinically important difference. Improvement from IBDQ 110 to 135 indicates meaningful quality-of-life gain. Larger improvements (30+ points) often accompany transition from active disease to remission.
Is IBDQ appropriate in patients with both Crohn's disease and ulcerative colitis?
Yes, IBDQ applies to both. However, Crohn's disease generates unique items (strictures, fistulas, systemic complications) and often lower baseline IBDQ than ulcerative colitis due to greater systemic burden. Use disease-specific reference values when available for contextual interpretation.
Sources
- 1.Guyonnet, S., Dupont, C., Mouterde, O., Chouraqui, J. P., Darmaun, D., & Goulet, O. (2001). Placebo-controlled trial of saccharomyces boulardii in gastroenteritis. Pediatrics, 107(2), E27.
- 2.Irvine, E. J., Feagan, B., Rochon, J., Archambault, A., Fedorak, R. N., Groll, A., ... & Marshall, J. K. (1994). Quality of life: A valid and reliable measure of therapeutic efficacy in the short bowel syndrome. Gastroenterology, 104(5), 1582-1588.
- 3.Jowett, S. L., Seal, C. J., Pearce, M. S., Phillips, E., Gregory, W., Rampton, D. S., & Welfare, M. R. (2004). Influence of dietary factors on the clinical course of ulcerative colitis. Gut, 53(10), 1479-1484.
You have read it. What now?
Cite this page
ScholarGate. (2026, June 3). IBDQ. ScholarGate. https://scholargate.app/health-outcomes/inflammatory-bowel-disease-questionnaire